Concepts (145)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Trypanosoma cruzi | 11 | 2022 | 20 | 4.320 |
Why?
|
| Chagas Disease | 9 | 2022 | 20 | 4.080 |
Why?
|
| Metabolomics | 8 | 2022 | 82 | 1.950 |
Why?
|
| Host-Pathogen Interactions | 4 | 2021 | 89 | 1.870 |
Why?
|
| Leishmania | 3 | 2022 | 6 | 1.630 |
Why?
|
| Tropism | 4 | 2021 | 8 | 1.630 |
Why?
|
| Chagas Cardiomyopathy | 2 | 2021 | 3 | 1.510 |
Why?
|
| Viral Tropism | 2 | 2021 | 3 | 1.490 |
Why?
|
| Environmental Exposure | 2 | 2022 | 47 | 1.400 |
Why?
|
| Tandem Mass Spectrometry | 3 | 2021 | 113 | 1.280 |
Why?
|
| Leishmaniasis | 2 | 2022 | 2 | 1.250 |
Why?
|
| Myocardium | 2 | 2021 | 179 | 1.240 |
Why?
|
| Leishmania donovani | 4 | 2015 | 9 | 1.040 |
Why?
|
| Communicable Diseases | 2 | 2022 | 19 | 0.940 |
Why?
|
| Microbiota | 3 | 2020 | 81 | 0.930 |
Why?
|
| Metabolome | 3 | 2021 | 66 | 0.890 |
Why?
|
| Heart | 3 | 2021 | 221 | 0.860 |
Why?
|
| Parasites | 2 | 2020 | 9 | 0.850 |
Why?
|
| Host-Parasite Interactions | 2 | 2021 | 11 | 0.850 |
Why?
|
| Trypanosoma | 2 | 2021 | 9 | 0.840 |
Why?
|
| Trypanosoma brucei brucei | 1 | 2022 | 6 | 0.780 |
Why?
|
| Workplace | 1 | 2022 | 20 | 0.770 |
Why?
|
| Bacteria | 3 | 2019 | 264 | 0.770 |
Why?
|
| Environmental Monitoring | 1 | 2022 | 62 | 0.760 |
Why?
|
| Euglenozoa Infections | 1 | 2021 | 1 | 0.740 |
Why?
|
| Animals | 16 | 2022 | 10093 | 0.730 |
Why?
|
| Listeria monocytogenes | 1 | 2021 | 58 | 0.720 |
Why?
|
| Respiratory Tract Infections | 1 | 2020 | 35 | 0.690 |
Why?
|
| Adaptation, Physiological | 1 | 2021 | 163 | 0.680 |
Why?
|
| Household Products | 1 | 2019 | 2 | 0.670 |
Why?
|
| Urbanization | 1 | 2019 | 6 | 0.670 |
Why?
|
| Energy Metabolism | 1 | 2021 | 186 | 0.660 |
Why?
|
| Leishmaniasis, Visceral | 3 | 2015 | 8 | 0.660 |
Why?
|
| Mass Spectrometry | 5 | 2022 | 188 | 0.630 |
Why?
|
| Biodiversity | 1 | 2019 | 100 | 0.630 |
Why?
|
| 14-alpha Demethylase Inhibitors | 2 | 2016 | 2 | 0.630 |
Why?
|
| Intestinal Diseases, Parasitic | 1 | 2018 | 1 | 0.600 |
Why?
|
| Humans | 21 | 2022 | 27165 | 0.590 |
Why?
|
| Gastrointestinal Tract | 1 | 2018 | 35 | 0.580 |
Why?
|
| Bacterial Infections | 1 | 2018 | 54 | 0.580 |
Why?
|
| Cell Communication | 1 | 2018 | 66 | 0.570 |
Why?
|
| Feces | 1 | 2018 | 107 | 0.560 |
Why?
|
| Carnitine | 3 | 2022 | 6 | 0.530 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2018 | 122 | 0.520 |
Why?
|
| Ergosterol | 1 | 2015 | 2 | 0.490 |
Why?
|
| Trypanosomiasis | 1 | 2014 | 1 | 0.460 |
Why?
|
| Mice | 7 | 2021 | 4478 | 0.430 |
Why?
|
| Leishmaniasis, Cutaneous | 1 | 2013 | 3 | 0.420 |
Why?
|
| Metabolic Networks and Pathways | 3 | 2021 | 46 | 0.400 |
Why?
|
| Mice, Inbred C3H | 2 | 2021 | 69 | 0.330 |
Why?
|
| Protozoan Proteins | 3 | 2019 | 50 | 0.310 |
Why?
|
| Lung | 2 | 2021 | 363 | 0.290 |
Why?
|
| Trypanocidal Agents | 2 | 2016 | 3 | 0.260 |
Why?
|
| Environmental Microbiology | 2 | 2019 | 24 | 0.200 |
Why?
|
| Software | 2 | 2020 | 121 | 0.200 |
Why?
|
| Amitriptyline | 1 | 2022 | 1 | 0.200 |
Why?
|
| Glutamine | 1 | 2022 | 32 | 0.190 |
Why?
|
| Computational Biology | 4 | 2020 | 150 | 0.190 |
Why?
|
| Phosphorylcholine | 1 | 2021 | 11 | 0.190 |
Why?
|
| Pseudomonas | 1 | 2021 | 13 | 0.190 |
Why?
|
| Antiprotozoal Agents | 1 | 2021 | 7 | 0.180 |
Why?
|
| Listeriosis | 1 | 2021 | 40 | 0.180 |
Why?
|
| Databases, Chemical | 1 | 2020 | 3 | 0.180 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 73 | 0.180 |
Why?
|
| Chronic Disease | 1 | 2021 | 264 | 0.180 |
Why?
|
| Disease Management | 1 | 2021 | 86 | 0.170 |
Why?
|
| Mice, Inbred BALB C | 3 | 2015 | 264 | 0.170 |
Why?
|
| South America | 1 | 2019 | 10 | 0.170 |
Why?
|
| Cathepsin L | 1 | 2019 | 2 | 0.170 |
Why?
|
| Rainforest | 1 | 2019 | 6 | 0.170 |
Why?
|
| Proteomics | 1 | 2021 | 177 | 0.170 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2019 | 13 | 0.170 |
Why?
|
| Biological Products | 1 | 2020 | 60 | 0.170 |
Why?
|
| Housing | 1 | 2019 | 22 | 0.160 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2019 | 32 | 0.160 |
Why?
|
| Fungi | 1 | 2019 | 50 | 0.160 |
Why?
|
| Drug Design | 1 | 2019 | 62 | 0.160 |
Why?
|
| Sterol 14-Demethylase | 2 | 2016 | 2 | 0.160 |
Why?
|
| Drug Discovery | 2 | 2016 | 32 | 0.160 |
Why?
|
| Cysteine Proteases | 1 | 2018 | 1 | 0.160 |
Why?
|
| Genomics | 1 | 2019 | 116 | 0.160 |
Why?
|
| Eukaryota | 1 | 2018 | 19 | 0.150 |
Why?
|
| Linoleic Acids, Conjugated | 1 | 2018 | 1 | 0.150 |
Why?
|
| Microbial Interactions | 1 | 2018 | 9 | 0.150 |
Why?
|
| Bile Acids and Salts | 1 | 2018 | 21 | 0.150 |
Why?
|
| Metagenomics | 1 | 2018 | 49 | 0.150 |
Why?
|
| Nucleosides | 1 | 2017 | 6 | 0.150 |
Why?
|
| Eicosanoids | 1 | 2017 | 10 | 0.140 |
Why?
|
| Phosphatidylcholines | 1 | 2017 | 41 | 0.140 |
Why?
|
| Principal Component Analysis | 1 | 2017 | 50 | 0.140 |
Why?
|
| Area Under Curve | 1 | 2017 | 94 | 0.140 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 105 | 0.140 |
Why?
|
| ROC Curve | 1 | 2017 | 140 | 0.140 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2017 | 128 | 0.140 |
Why?
|
| Directed Molecular Evolution | 1 | 2016 | 5 | 0.140 |
Why?
|
| Organic Chemicals | 1 | 2016 | 14 | 0.140 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2018 | 320 | 0.140 |
Why?
|
| Genome, Protozoan | 1 | 2015 | 5 | 0.120 |
Why?
|
| Disease Models, Animal | 2 | 2018 | 1406 | 0.120 |
Why?
|
| Male | 3 | 2021 | 13041 | 0.120 |
Why?
|
| Pseudogenes | 1 | 2014 | 3 | 0.120 |
Why?
|
| Ecosystem | 1 | 2016 | 206 | 0.120 |
Why?
|
| Machine Learning | 1 | 2015 | 81 | 0.110 |
Why?
|
| Gene Deletion | 1 | 2014 | 116 | 0.110 |
Why?
|
| Signal Transduction | 2 | 2018 | 1379 | 0.110 |
Why?
|
| Psychodidae | 1 | 2013 | 1 | 0.110 |
Why?
|
| Disease Vectors | 1 | 2013 | 4 | 0.110 |
Why?
|
| Neglected Diseases | 1 | 2013 | 2 | 0.100 |
Why?
|
| Disease Progression | 1 | 2014 | 458 | 0.100 |
Why?
|
| Cells, Cultured | 1 | 2015 | 978 | 0.100 |
Why?
|
| Phenotype | 1 | 2014 | 668 | 0.100 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2014 | 537 | 0.100 |
Why?
|
| Unfolded Protein Response | 1 | 2011 | 24 | 0.090 |
Why?
|
| Macrophages | 1 | 2013 | 280 | 0.090 |
Why?
|
| Molecular Docking Simulation | 2 | 2019 | 47 | 0.080 |
Why?
|
| Female | 3 | 2015 | 14661 | 0.060 |
Why?
|
| Bayes Theorem | 2 | 2015 | 95 | 0.050 |
Why?
|
| Amino Acid Sequence | 2 | 2016 | 679 | 0.050 |
Why?
|
| Mammals | 1 | 2022 | 46 | 0.050 |
Why?
|
| Metadata | 1 | 2020 | 3 | 0.040 |
Why?
|
| Models, Chemical | 1 | 2020 | 89 | 0.040 |
Why?
|
| Cysteine Endopeptidases | 1 | 2019 | 17 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2020 | 251 | 0.040 |
Why?
|
| Kinetics | 1 | 2019 | 538 | 0.040 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2016 | 29 | 0.030 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2016 | 54 | 0.030 |
Why?
|
| Plasmodium falciparum | 1 | 2016 | 17 | 0.030 |
Why?
|
| Ions | 1 | 2016 | 18 | 0.030 |
Why?
|
| Chromatography, Liquid | 1 | 2016 | 75 | 0.030 |
Why?
|
| Crystallography, X-Ray | 1 | 2016 | 218 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 751 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 589 | 0.030 |
Why?
|
| High-Throughput Screening Assays | 1 | 2015 | 36 | 0.030 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2016 | 172 | 0.030 |
Why?
|
| Cell Line | 1 | 2015 | 683 | 0.030 |
Why?
|
| Protein Denaturation | 1 | 2011 | 28 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2011 | 130 | 0.020 |
Why?
|
| Endoplasmic Reticulum | 1 | 2011 | 77 | 0.020 |
Why?
|
| Protein Biosynthesis | 1 | 2011 | 109 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2011 | 283 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2011 | 568 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2011 | 1041 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2011 | 648 | 0.020 |
Why?
|
| Phylogeny | 1 | 2011 | 462 | 0.020 |
Why?
|
| Models, Biological | 1 | 2011 | 448 | 0.020 |
Why?
|